Abstract Drug abuse (e.g., methamphetamine-Meth or cocaine-Coc) is one of the major risk factors for becoming infected with HIV-1, and studies show that in combination, drug abuse and HIV-1 lead to significantly greater damage to CNS. To overcome these issues, we have developed a novel nanoformulation (NF) for drug-abusing population infected with HIV-1. In this work, a novel approach was developed for the co-encapsulation of Nelfinavir (Nel) and Rimcazole (Rico) using layer-by-layer (LbL) assembled magnetic nanoformulation for the cure of neuroAIDS. Developed NF was evaluated for blood-brain barrier (BBB) transmigration, cell uptake, cytotoxicity and efficacy (p24 assay) in HIV-1 infected primary astrocyte (HA) in presence or absence of Coc and Meth. Developed magnetic nanoformulation (NF) fabricated using the LbL approach exhibited higher amounts of drug loading (Nel and Rico) with 100% release of both the therapeutic agents in a sustained manner for 8 days. NF efficacy studies indicated a dose-dependent decrease in p24 levels in HIV-1-infected HA (~55%) compared to Coc + Meth treated (~50%). The results showed that Rico significantly subdued the effect of drugs of abuse on HIV infectivity. NF successfully transmigrated (38.8 ± 6.5%) across in vitro BBB model on the application of an external magnetic field and showed >90% of cell viability with efficient cell uptake. In conclusion, our proof of concept study revealed that sustained and concurrent release of sigma σ1 antagonist and anti-HIV drug from the developed novel sustained release NF can overcome the exacerbated effects of drugs of abuse in HIV infection and may solve the issue of medication adherence in the drugabusing HIV-1 infected population.
Introduction
HIV-1 can enter cells of the central nervous system (CNS) and cause progressive combined cognitive and motor impairment in infected individuals. Macrophage and microglial cells are the main sources of HIV-1 infection in the CNS though astrocytes are the most abundant kind of cells in the CNS and connect the cells of the brain to a compound intercellular complex. Since astrocytes are important cells for CNS function, their role in the context of HIV-1 neuropathogenesis need to be studied (Díaz et al. 2015) . HIV infection and neuroinflammatory responses lead to the development of various neurological disorders collectively termed as HIVassociated neurocognitive disorders (HANDs) (Díaz et al. 2015; Lindl et al. 2010; Nair et al. 2016) . While the use of highly active antiretroviral therapy (HAART) has significantly reduced HIV-1 associated dementia (the most severe form of HAND), the milder forms of HAND continue to be a major health concern (Ances and Clifford 2008; Joska et al. 2010; Kaushik et al. 2016b ). In addition, drugs of abuse promotes the virus replication and have deleterious effects on CNS and its environment (Buch et al. 2012; Lucas et al. 2001) . In the USA, psychostimulants such as cocaine (Coc), Rahul Dev Jayant and Venkata S. R. Atluri are equal authors.
* Rahul Dev Jayant rjayant@fiu.edu * Madhavan Nair nairm@fiu.edu methamphetamine (Meth), and other illicit drugs are highly abused among the HIV-infected population. Studies have demonstrated that Coc and/or Meth ingestion results in the acceleration of HIV infection and progression towards NeuroAIDS (Ciccarone 2011; Ferris et al. 2008; Gannon et al. 2014) . CNS cells exposed to drug abuse release abnormal levels of pro-inflammatory mediators, e.g., cytokines and chemokines, resulting in neuroinflammation (Borgmann and Ghorpade 2015; Ramesh et al. 2013) . It also affects permeability of the blood-brain barrier (BBB) that promotes enhanced transmigration of HIV-infected leukocytes/ monocytes into the CNS Ramirez et al. 2009 ). Despite the need, there is no FDA-approved pharmacotherapy against psychostimulant dependence in HIV patients that can be employed to target polydrug abusers (Stoops and Rush 2013) . Sigma-1 (σ1) receptors have been well documented as a protein's target for Coc involved in the toxicity and stimulant actions of Coc (Narayanan et al. 2011) . Already, it has been shown that sigma (σ1) receptor antagonists can attenuate or block the behavioral sensitization caused by Meth in rat models (Maurice and Su 2009) . The increased activation of dopamine receptors is accountable for most of the neurotoxic effects of Meth, including psychomotor stimulation and addiction. Therefore, a single antagonist that can block or mitigate the effects of drug abuse (e.g., Meth and Coc) can act as a promising therapeutic agent for polydrug users. As per previous studies, Rimcazole dihydrochloride (Rico) acts as a potent antagonist of σ1 receptors in a dose-dependent manner. It shows good affinity for the dopamine transporters and has capability to inhibit dopamine uptake; therefore, it may also act as a Meth antagonist. Considering the dual antagonistic property, we decided to test the efficacy of Rico and co-deliver it with antiretroviral drug (Nelfinavir, a protease inhibitor) across the BBB into the CNS to control HIV infection and mitigate the stimulatory and neurotoxic effects of Meth and Coc.
Due to the selective semi-permeability of the BBB, desired therapeutic concentrations of the antiretroviral (ARV) drugs and potent drug abuse antagonist have negligible ability to reach the CNS, leading to efficacy issues, high dosing frequency, and regiment adherence leading to neurocognitive issues (Ingersoll and Cohen 2008) . Our group has already demonstrated that magnetic nanocarriers loaded with anti-HIV drugs can be facilitated across the BBB upon applying non-invasive external static magnetic field, without hampering the integrity of the BBB (Atluri et al. 2016; Ding et al. 2014; Jayant and Nair 2016; Jayant et al. 2015; Kaushik et al. 2014 Kaushik et al. , 2016a Nair et al. 2013; Saiyed et al. 2009; Tomitaka et al. 2017) . Even though the Magnetic Nanoparticles (MNPs) have large surface areas, loading higher amounts of different classes of drugs onto a single nanoparticle is still a daunting task. To overcome the challenge of multi-drug loading on a single nanoparticle's surface, we have explored layer-by-layer (LbL) self-assembly technique (Decher 1997; Hammond 2012) . Based on our previous success in LbL-based NF development as demonstrated in our previous work (Jayant et al. 2009 (Jayant et al. , 2011 Madhavan 2016, Jayant and Srivastava 2007) , we have developed a novel nanoengineered sustained release magnetic NF to deliver Nel and Rico across the BBB under the influence of an externally applied noninvasive static magnetic field. The rationale of developing this multi-therapeutic nanoformulation is to increase the adherence of medication to HIV-1-infected drug abusing population, which is a major concern for the current HIV-1 therapy. Therefore, we expect that by formulating such sustained release, nanoformulation can serve as platform technology for more effective HIV therapy and may be useful for the treatment of neuroAIDS in drug-abusing HIV patients.
Materials and methods

Cell culture and reagents
Primary human astrocytes (HAs) were procured from ScienCell Research laboratories (Carlsbad, CA; cat no. 1800-5) and grown in astrocyte medium (ScienCell laboratories, cat no. 1801) containing 2% fetal bovine serum (ScienCell cat no. 0010), 1% astrocyte growth supplement (ScienCell cat no. 1852), and penicillin/streptomycin (ScienCell cat no. 0503). HIV-1 Ba-L (clade B) (NIH AIDS Reagent Program cat no. 510) was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH.
HIV-1 infection of HA
A standard lab protocol was used for infecting the HA cells with HIV with minor modifications (Atluri et al. 2013) . Briefly, on 4th passage HAs (1 × 10 5 cells), cells were grown overnight in six-well plates in minimum essential media (MEM); Polybrene (10 μg/ml) treatment for 6 h before the infection was done to activate the cells. Optimized dose (20 ng) of HIV-1 clade B virus was used to infect the cells overnight, and then the cells were washed with phosphate-buffered saline (PBS) to remove the unbound virus; fresh media was added and cells were further incubated for a total of 5 days.
Coc and Meth dose optimization
To study the effects of drugs of abuse (Meth and Coc) on HIV infectivity and the antagonist activity of Rico, dose optimization studies were performed with HAs cells. HIV-infected (5 days post-infected, DPI, control) HA cells were treated with different concentrations of Meth (10, 25, 50, 100 and 250 μM) and Coc (0.1, 1, 2.5, 5 and 10 μM). On the sixth day, the HIV-infected cells were treated with optimized concentration of drugs (Coc, Meth, or Rico alone or in combination) and incubated for 48 h. The culture supernatant was collected after 48 h and the p24 antigen was estimated using an ELISA kit (ZeptoMetrix Corp. cat no. 0801200). Non-HIV-infected cells were used as control samples for all experiments. MTT assay (details are given in BIn vitro cytotoxicity assay^section below) was performed to check the viability of the cells after drug treatment, which helped in determining the optimal dose with higher infectivity and less toxicity.
Antagonist (Rico) to drug of abuse (Meth and Coc) ratio optimization Sigma receptors are known to be involved in the toxic effects induced by drugs of abuse such as Coc and Meth (with moderate affinity). Different concentrations of Rico were added to HIV-infected HAs 1 h prior to Coc and Meth treatment to determine the effective concentration of Rico to block/ attenuate the activity of Coc and/or Meth by binding to the sigma-1 receptor. We have used various concentration ratios of Rico and Coc and/or Meth (1:1, 1:2, 1:3, and 1:4) for this purpose. To see the activity of Rico against Coc-and/or Methtreated HIV-infected cells, p24 antigen production was measured in these cells using the p24 antigen ELISA kit (ZeptoMetrix Corp. cat. no. 0801200).
Flow cytometry for the quantification of sigma-1 receptor expression
To see the effects of Coc and Meth exposure on the expression profile of sigma-1 receptors on CNS cells, HA cells were treated with optimal doses of Coc and Meth for 48 h, and then cells were washed with PBS and harvested. Cells were counted and aliquoted (1 × 10 6 cells) in polystyrene falcon conical tubes (12 × 75 mm; BD Biosciences, catalog no. 352058). Cells were blocked with heat-inactivated human serum and incubated on ice for 10 min. Subsequently, the cells were spun down (2000 rpm for 5 min) and the supernatant was discarded. Cells were incubated in the dark with anti-sigma-1 antibody (1:500 dilution, cat. no. PAS-30372, Thermo Fisher, USA) on ice for 20 min, followed by washing with wash buffer twice and fixed with 4% paraformaldehyde. Cells that were positive for the sigma-1 receptor were analyzed using BD Accuri flow cytometer (Ann Arbor, MI). A total of 10,000 events were collected for each treatment sample, and the results were analyzed using the FlowJo software (Tree Star, Inc.; Ashland, OR).
Synthesis of MNPs, characterization, and drug binding studies
The ultra-small MNPs (Fe 3 O 4 ) were synthesized using the co-precipitation method as per our previously published protocol . Nanoparticle size was determined using transmission electron microscopy (TEM, Phillips CM-200200 kV at 80 kV). Briefly, a small drop of highly diluted MNPs solution was spread on a carbon support film (400 mesh Cu grids Type B, Ted Pella, Inc., USA) and used for the analysis. Dynamic light scattering (DLS) (Zetasizer NanoZS, Malvern) was carried out at 25°C to measure the size distribution, hydrodynamic radius, and surface charge measurements of the MNPs. For the drug binding studies, 1 mg of MNPs was added to 1 mg/ml solution of Nel [protease inhibitors (PIs)] in PBS buffer (pH 7.4) and amount or % binding of drugs to the MNPs was determined by calculating the concentration of Nel in the unbound fractions (supernatant) of the mixture by UV spectrophotometry at 260 nm at different time intervals at RT. A similar binding protocol was performed to calculate Rico % binding at UV absorbance of 240 nm.
LbL assembly on MNPs
Loading of both the therapeutic agents (Nel and Rico) on to the magnetic nanoparticle was completed using previously established LbL protocol . The polyelectrolyte used for the experiment was dextran sulfate sodium (DS, Polycation: 2 mg/ml in 0.15 M NaCl, Mol wt-500,000, Sigma Aldrich), Nel (Polyanion: 1 mg/ ml in PBS, Mol. Wt. 287.213 g/mol), and Rico (in PBS, Mol. Wt. 394.38). Briefly, a DS solution (2 mg/ml) was dissolved in 0.15 M NaCl at pH 7.4. For the first layer coating, 100 μl (1 mg/ml) of DS solution was added to 1 mg of the Nel-loaded MNPs and kept on a vertical rotator under constant rotation (200 rpm) for 20 min. To separate out the unbound DS, nanoparticle solution was washed three times with Milli-Q water using centrifugation at 2500 rpm for 5 min. Successively, 100 μl (1 mg/ml) of negatively charged drug (i.e., Nel or Rico, polyanion solution) was added to form a second layer of drug on to the magnetic nanocarriers and again kept on a vertical rotator under constant rotation (200 rpm) for 20 min. The steps mentioned above were repeated twice to have two bilayer coatings of drugs on MNPs surface. The surface charge of the nanoformulation was measured using the zeta potential analyzer after rinsing and prior to depositing the second DS layer. The final assembled magnetic nanoformulation (NF) was washed via distilled water by centrifugation and used for in vitro release and other efficacy-related studies.
In vitro drug release study
In vitro drug release studies of finally assembled NF were performed using a micro Float-A-Lyzer dialysis device (MWCO-100 KD) containing 50 ml of 0.01 M PBS buffer (pH 7.4) at 37°C. At predetermined time intervals, 500 μl of released drug was collected and substituted with a fresh PBS solution every time to maintain the sink condition. The % cumulative release of each drug was determined via UV spectrophotometry at λmax of 260 nm and 240 nm for Nel and Rico, respectively.
Intracellular NF uptake studies
Primary human astrocytes (HAs) (1 × 10 6 cells) were seeded in six-well plates and incubated for 24 h. After incubation, NF was added to cells and incubated further for 3 h in the presence or absence of external magnetic force. After rinsing the cells with PBS (pH 7.4), cells were observed under fluoroscent microcope.
In vitro BBB preparation and NF transmigration studies
Primary human brain microvascular endothelial cells (HBMECs, ScienCell, cat. no. 1000) and primary human HA (ScienCell, cat. no. 1800) cells were cultured as per the provider's protocol. The in vitro BBB model was established as described earlier by Persidsky et al. (Persidsky et al. 1997 ) and modified by us. In brief, the in vitro BBB model was established using bicompartmental transwell culture plate (cat. no. 3415, Corning Life Sciences, USA). In a sterile 24-well cell culture plate and transwell coated with PLL (1 μg/ml), with a pore density of 2 × 10 6 pores/cm 2 and a cell growth area of 0.33 cm 2 , 2 × 10 5 HBMECs and HAs were grown to confluence on the upper side and underside of the apical chamber, respectively. After the transmigration assay was completed, the paracellular transport of FITCdextran (average MW. 70,000, Cat#46945, Sigma Aldrich, USA) was measured in order to assess the effects of NF on the integrity of the in vitro BBB model as previously described by us (Atluri et al. 2016) . Integrity of the BBB membrane was calculated via measuring TEER (transendothelial electrical resistance) using Millicell ERS microelectrodes system (Millipore). Transmigration studies with drug-loaded MNPs and control MNPs were conducted on the fifth to seventh day of the BBB culture, depending upon the achievement of ideal BBB integrity as established by TEER measurement. Samples (plain MNPs or NF) were added to the apical chamber of transwell in presence or absence of magnetic field (0.8 T) in the incubator at 37°C. Magnet was placed below the transwell, and % transmigration of MNPs/NF was analyzed using an ammonium thiocyanate-based photometric assay.
In vitro efficacy evaluation of NF in the presence and absence of drugs of abuse To confirm the inhibition effect of Rico on drugs of abuse (Coc and Meth) and to check the antiviral efficacy of NF against HIV infectivity, we conducted the p24 antigen assay using a standard protocol. HAs (10 × 10 6 cells) were infected with HIV-1Ba-L overnight as described earlier (Atluri et al. 2013) , washed with PBS (pH 7.4), and further incubated with and without Coc + Meth treatment, plus NF treatment at a concentration of 100 μg/ml. The culture supernatants from days 1, 2, 3, 5, and 8 after 5 DPI (total 14 of HIV infection) were quantified for p24 antigen (pg/ml) using p24 ELISA kit (ZeptoMetrix, NY).
In vitro cytotoxicity assay NF cytotoxicity was evaluated using cell proliferation MTT assay kit (catalog no. G 3580, Promega, USA). Briefly, HAs 5 × 10 3 cells per well were seeded in 96-well plates and incubated for 24 h at 37°C. After incubation, the old culture medium was replaced with 100 μl fresh medium, and different concentrations of NF (50-250 μg/ml) were added, and treatment was performed for 24 and 48 h. After treatment, 20 μl of MTT solution (5 mg/ml in PBS) was added into each treated well and incubated for 2 h at 37°C. Lastly, 100 μl of stop solution (20% SDS in 50% dimethyl formamide) was added into each treated well and absorbance was measured at 550 nm using a microplate reader (Synergy HT, Multi-mode microplate reader, BioTek Instrument, Inc., Winooski, Vermont, USA).
Statistical analysis
Experiments were performed in three independent experiments with triplicates and the values obtained were averaged. All the results were expressed as mean ± standard error of the mean (SEM). Statistical analysis of two groups was performed by Student's t test, while statistical analysis of more than two groups was analyzed using one-way ANOVA followed by Bonferroni's multiple comparison test. Differences were considered significant at p ≤ 0.05. Data analysis was performed with GraphPad Prism software (La Jolla, CA).
Results
HIV infectivity in HAs treated with Coc and/or Meth in combination with Rico
We studied the effects of exposure of Coc and Meth on HIV infectivity; HA cells were infected with HIV and treated with different concentrations of Coc and Meth. In the quantitative estimation of p24 antigen production, we observed a significant increase in HIV level in Coc (at 1 μM concentration) and Meth (at 25 μM) in HA cells. We determined that these concentrations were optimal concentrations and used them for further experiments (as shown in Fig. 1a, c) . Additionally, we studied the cytotoxicity of various concentrations of Coc (0.1-10 μM) and Meth (10-250 μM). Results showed that Coc (up to 5 μM) and Meth (up to 50 μM) treatment (as shown in Fig. 1b, d , cell viability ≥80%) did not show any significant cytotoxicity. HAs cells were treated with the optimal concentrations of Coc (1 μM) and Meth (25 μM), and then Rico (the antagonist) was added in different ratios (1:1, 1:2, 1:3, and 1:4 ratios) to study its effect in reducing the exaggerating effect of drug of abuse on HIV infection. We observed significant reduction in HIV infectivity (1 .5 ± .25-fold) in Coc and Rico (up to 2 μM) and Meth and Rico (up to 50 μM)-treated samples (Fig. 1e, f) . We concluded that the optimal concentrations of Rico to inhibit the activity of Coc and Meth were 2 and 50 μM, respectively without any toxicity (Fig. 1g) . We used these Rico concentrations to attenuate HIV infection levels alone and on co-exposure with Coc and Meth together and achieved significantly reduced HIV infection (Fig. 2a) .
Expression of sigma-1 receptor in HA treated with Coc and/or Meth Fluorescence-activated cell sorting (FACS) analysis was performed to assess σ-1 receptor expression upon treatment with the drugs of abuse. Coc and Meth treatment for 48 h showed 4.09 and 5.49% increase in expression respectively, whereas the co-treatment of Coc and Meth resulted in a synergistic increase in the receptor expression (15%) as shown in Fig.  2(b) when compared to the control cells.
Nanoformulation preparation, characterization, and drug release studies
LbL-assembled NF loaded with Nel and Rico was developed as illustrated in Fig. 3a . The MNPs were synthesized, characterized (size, shape, charge), and analyzed for drug binding efficacy. TEM morphological characterization showed a round structure with an average size of 10 ± 3 nm (Fig. 3b) . Dynamic light scattering (DLS) analysis also confirmed that MNPs have a hydrodynamic size of 12 ± 5 nm, with excellent dispersion properties (polydispersity index >0.18 in aqueous medium). The effects of drug loading and LbL deposition on nanoformulation hydrodynamic diameter size was also evaluated using DLS. The loading efficiency of Nel (31 ± 2%) and Rico (35 ± 4%) were obtained in non-LbL MNP formulation. Results showed that (Fig. 3c) , in the case of Nel, application of two layers (2BL) of dextran sulfate sodium leads to~1.9 times (30 μg to 58.5 μg/mg MNPs) higher drug loading compared to 1BL formulations. Similar results were obtained with Rico (2BL), as drug loading increased~1.4 times (32 μg to 47 μg). LbL deposition was established using zeta (ζ) potential a b Fig. 2 a In vitro Rico efficacy studies for attenuating Coc and Meth induced HIV infection. HA (1 × 10 5 cells) were grown in six-well culture plates and infected with 20 ng of HIV-1B for overnight. Unbound virus was washed with PBS and cells were infected for 5 days. After 5 days of infection, HIV-infected astrocytes were pretreated (1 h) with Rimcazole (2 and 50 μM) and then treated with optimized dose of Coc (1 μM) and Meth (25 μM), respectively. To study the Rico attenuation capacity, supernatant from each treated well was collected after 24 h of treatment and HIV infection levels were measured by p24 ELISA (*p ≤ 0.05; **p ≤ 0.01; NS not significant). b Flow-cytometry analyses to assess expression of sigma (σ1) receptors: primary astrocytes were treated with either cocaine and/or meth for 48 h. Following treatment, cells were collected and stained with FITC-labeled sigma receptor. Accuri (BD Biosciences) was used for fluorescence acquisition, and data was analyzed with FlowJo software (BD Biosciences). Red line indicates the untreated control, and blue line indicates the treated cells (test). Untreated control was gated based on the isotype control, and the treated cells (test) were gated based on the untreated cells analysis; results showed that the ζ-potential value for drug MNPs loaded with Nel was 16.5 ± 1.5 mV, and charge reversed upon adsorption of drug DS coating to −22.3 ± 1.5 mV. Continuous charge reversal occurred upon consequent layer deposition (Fig. 3d) , thus confirming that layer deposition occurred as anticipated. In vitro drug release studies show that uncoated MNPs released 100% Rico and Nel in 5 and 6 h, respectively (as shown in Fig. 3e) . Results proved that application of LbL assembly on MNPs increased the drug release duration from 120 to 192 h for Nel and from 108 to 180 h for Rico (Fig. 3f) .
In vitro BBB development and NF transmigration studies
Transmigration studies of samples (Plain MNPs and NF) were performed using developed in vitro BBB model. The BBB formation and its integrity were confirmed using TEER value calculation. After achieving the desired (300 ± 10 Ω/cm 2 ) TEER values, plain MNPs and NF were added to different BBB transwell under ±0.8 T magnetic field as shown in Table 1 .
Results showed that there was no significant difference in TEER values, with respect to drug-loaded MNPs NF when compared to plain (uncoated and unloaded) MNPs (Table 1) . The effect of external magnetic field on NF BBB transmigration was verified by measuring the amount of MNPs that transmigrate across the BBB membrane in basolateral chamber. Figure 4a showed that 40 ± 4.5% of plain MNPs and 38.8 ± 6.5% of NF crosses the BBB in the presence of magnetic fields after 2 h. In absence of external magnetic force, only 3.0 ± 1.5% plain MNPs or NF were able to cross the BBB after 2 h of treatment, thus showing that the application of an external magnetic field can help deliver the NF across the BBB. To further evaluate the integrity of the BBB after NF transmigration under magnetic field, paracellular transport of FITC-dextran experiment was performed. Results showed that 8.5 ± 3.5% FITC molecules transmigrated (apical to basolateral chamber) in NF-treated well compared to~100% negative control (without any BBB cells) as shown in Fig. 4b , thus proving that transmigration of NF under an external magnetic field does not affect BBB integrity. Additionally, the effects of longer treatments of magnetic field for higher NF transport across the BBB was also studied and results showed that longer magnetic treatment period (up to 6 h, using 0.8 T) does not lead to higher transmigration (Fig. 4c) .
In vitro antiviral efficacy of NF in the presence of drugs of abuse, cell uptake, and cytotoxicity studies To overcome the exacerbated effects of drugs of abuse in HIV infection, NF efficacy was determined via quantification of p24 antigen level in infected HA cells. HAs were infected with HIV for 5 days; further, the same cells were treated everyday with optimized doses of Coc (1 μM) and Meth (25 μM) from the 6th to 13th day (Total NF treatment time was 8 days). NF was added (100 μg/ml) 5 days after infection (DAI) to HIV- infected cells in presence or absence of Meth or Coc or Meth + Coc, and the supernatant was collected on the 6th, 7th, 8th, 10th, and 13th days of treatment (8 days of NF treatment) to check the antiviral inhibitory efficacy of the NF. ELISA p24 assay results (Fig. 5a) showed a significant increase in the p24 viral protein production when compared with HIV-infected control cells over the entire Meth and/or Coc treatment period of 8 days. Results showed that Rico release, along with Nel from the NF, attenuates the additive viral activity of HIV in the presence of drugs of abuse (Coc + Meth). The sustained-release ability of the NF was evaluated over a treatment period of 8 days. Result showed 50% (550-650 to 210-250 pg/ml) reduction in viral load over a period of 8 days after NF treatment, thus confirming NF capability to attenuate the drug abuse effect and suppress the viral replication in HIV infection.
Further, to study the qualitative NF cell uptake, different concentrations (50-200 μg/ml) of NF were tested in HA cells over a period of 24 h. Results (Fig. 5b) showed representative fluoroscent microscope image of NF (100 μg/ml); additionally, flow cytometry studies were performed for quantitative analysis, and the result showed that maximum cell uptake took place within 6 h and longer incubation time (24 h) did not result in higher cell uptake (percentage of cells positive for FITC-tagged NF, data not showed). Consequently, we also evaluated the cytotoxicity of the developed NF using the MTT cytotoxicity assay on HA cells using different concentrations for 24 and 48 h of treatment period. Results (Fig. 5c) showed that none of the tested NFs (10, 20, 50 and 100 μg/ml) showed any significant cytotoxicity at cellular and morphological levels, and the percentage of viable cells was comparable to the control group (untreated cells), thus suggesting that developed NF is non-toxic in nature and is safe to be used for in vivo applications.
Discussion
Abusing drugs is a very common phenomenon among HIV-positive individuals, as nearly 50% of PLWH/A are reported to have histories of drug and/or alcohol disorders (Bing et al. 2001; Rabkin et al. 2004 ). Substance abuse is allied with marked deterioration in key health, behaviors and consequences include non-adherence, immunosuppression, augmented sexual behaviors, and augmented burdens on healthcare (Conigliaro et al. 2004; Kelley and Petry 2000; Masson et al. 2004) . It is known that HIV seropositive drug users have greater age-matched morbidity and mortality when equated to non-drug-using HIV-positive patients (Durvasula and Miller 2014) . After magnetic treatment 302.2 ± 8.5 301.2 ± 10.5 306.2 ± 12.5 Fig. 4 a NF transmigration analysis using in-vitro BBB model. NF was added in the upper chamber of the BBB model, and after 3 h of magnetic treatment, migrated plain MNPs and NFs in presence or absence of static magnetic field (0.8 T) were calculated for iron content in the lower chamber. Results are expressed as mean ± SE of three independent experiments. Statistical significance was determined using unpaired Student's t test. b BBB integrity using FITC-dextran transport model. FITC-dextran transport was measured in BBB model and after 3 h of magnetic treatment, FITC-dextran was added on the upper chamber of the insert. After 3 h of incubation, relative fluorescence units (RFUs) from the basal chambers of the inserts were measured. Results are expressed as % FITC-dextran transport with respect to the untreated control cultures (−ve control = no cell and +ve control = with BBB cells) and represented as mean ± SE of independent experiments. c Effect of time with respect to nanoformulation BBB transmigration. NF was added in the upper chamber of the BBB model; after every 1 h till 6 h of treatment, migrated NFs in presence of static magnetic (0.8 T) were calculated for iron content in the lower chamber. Results are expressed as mean ± SE of three independent experiments. Statistical significance was determined using unpaired Student's t test Substance abuse among PLWH/A has been associated with non-adherence to HAART. Alcohol and drug abuse disorders are consistently linked with poor HAART adherence and poor immunologic and virologic consequences (Binford et al. 2012) . HAART has considerably enhanced the prognosis of HIV-1 patients and reduced the prevalence of HAD and its associated asymptomatic neurocognitive impairment. In addition to HAART, the pursuit for effective neuroprotective agents or anti-drugs of abuse agents is critical to combat with the additive effects on HIV progression. Sigma-1 receptors are extensively dispersed in memory-associated cortical and motorrelated brainstem areas (hypothalamic nuclei, dentate gyrus of the hippocampus, and facial nucleus), which are the same sites for HAND or HIV/gp120-induced neuronal damage Zhang et al. 2012) . Developing approaches that will eliminate or reduce the effects of individual adherence could upsurge the effectiveness of treatment strategies against HIV transmission. Considering these possibilities, our work involves testing the hypothesis of concurrently delivering sigma receptor antagonist (Rico) and an antiretroviral drug (Nel) into CNS, to simultaneously provide neuroprotection in neuropathy and neurotoxicity induced by HIV viral proteins (gp120 or Tat) in presence of drugs of abuse (Meth and Coc), with the ultimate purpose of decreasing HIV viral load from the brain. On the sixth day of infection, optimized Coc (1 μM) and Meth (25 μM) were added to cells and treated every day for the next 8 days (total 14 days of HIV infection). Drug-loaded NF (100 μg/ml) was added only once (on the sixth day) to the respective wells, and reduction in HIV infection levels was measured by using the p24 ELISA. Results were analyzed with respect to HIV-1 infection v/s HIV+(Meth + Coc) and HIV+ (Meth + Coc) v/s NF treatment (*p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001; ****p ≤ 0.0001; NS not significant). b Qualitative analysis of cellular uptake of FITC-tagged LbL-NF in HA by fluorescence microscopy. FITC-tagged LbL-NF (concentration 100 μg/ml) in HA after 6 h of treatment. A Control cell bright field image. B Cell nuclei stained with DAPI (blue). C FITC tagged drug loaded NF (green). D Composite image show green and blue fluorescence inside the cells, confirming the cellular uptake of the NF. Images taken at ×10 magnification using fluorescence microscopy (Zeiss, Wetzlar, Germany). c In vitro cytotoxicity of NF. Results show the percentage of cells viability after treatment with different NF concentrations (10, 20, 50, and 100 μg/ml). HAs (1 × 10 5 cells) were grown in six-well culture plates and cells were infected with 20 ng of HIV-1 overnight. Uninfected virus was washed and cells were infected for 7 days. On the fifth day of infection, NF was added at different concentrations to the respective wells and incubated for 24 and 48 h, respectively. After a total of 6 and 7 days of post-infection (DPI), cell viability was measured by using the MTT assay (*p ≤ 0.05; NS not significant)
In this study, an effective dose of Meth and Coc was optimized to study their effects on HIV infectivity and viral replication. The ratio of Rico (the antagonist) to attenuate the effects of Meth and Coc inhibition in the presence of HIV was optimized. Receptor expression results showed that cotreatment with Coc and Meth led to higher expressions of sigma receptor. Ultra-small MNPs were synthesized by the co-precipitation method, and NF was evaluated for % drugloading, in vitro release study, cytotoxicity, and in vitro antiviral efficacy in the presence or absence of drugs of abuse in HA cells. Surface charge distribution of synthesized MNPs and developed NF was determined by measuring the ζ (zeta) potential. Results showed that the ζ values reversed coating on addition of alternately charged moieties (Nel/DS coating + Rico/DS coating) on each layer deposition, thus demonstrating that multilayer build-up is achieved and drugs are loaded in the desired manner. Electrostatic interactions between magnetic nanoparticles and polyelectrolytes are key factors for multilayer deposition. Due to high drug loading and LbLcoating barrier, we expected that the drugs would release in a slow and sustained manner over a period of 7-10 days. Our results showed that 2BL NF releases both of the drugs over a period of 8 days compared to 5-6 h on non-LbL NF. thus proving that the LbL technique helps in achieving fine tuning of desired release rate of drugs and is also helpful in reducing the initial burst release of drugs without affecting the release kinetics.
Further, cytotoxicity and cell uptake studies were done to assess the in vitro biocompatibility of NF in HA cells. Different cytotoxicity parameters (e.g., cell viability, adhesion, proliferation, morphology, and cellular uptake) were analyzed. The results showed good adhesion, growth, and morphology of treated cell with >90% cell viability over a period of 48 h. Moreover, the effects of the magnetic force on BBB transmigration and its integrity was measured, and we observe no BBB damage and >40% of the NF migrated across the BBB on magnetic treatment for 2 h. Results confirm that our developed NFs are proficiently taken up by HA cells, hence providing a platform to effectively deliver any drug cargo of interest. Finally, we have shown that NF release can reduce HIV replication (p24 antigen level) in the presence and absence of drugs of abuse (Coc and Meth) in HIV-infected HA cells. The NFs were able to control the HIV replication for 8 days in a continuous manner without showing any cytotoxic effects to the treated HA cells, and the results correlated well with the in vitro drug release period.
Conclusion
Our work demonstrates that concurrent delivery of Rico and Nel can be achieved through LbL assembly technique. We also showed the magnetically guided delivery of developed NF across the BBB with sustained release up to 8 days with synergistic effects of both drugs (Rico and Nel) in mitigating the effects of drug abuse in HIV infection. We believe that combination therapy of ARV drugs (i.e., [NNRTI + NRTI + PI] or [NRTI + PI + Integrase inhibitor]), latency reactivating agents (LRAs e.g., bryostatin, disulfiram, PMA, etc.) along with drug abuse antagonists will certainly enhance the treatment efficacy and help in the eradication of neuroAIDS in drug-abusing patients. To bring this platform nanotechnology technique to clinical level, we still need to check the efficacy of the developed nanoformulation in vivo studies. Developing latent humanized HIV-1 animal model still poses a big challenge; our lab is working towards this problem and has generated few models based on an HIV-SCID mouse model. For our future work, we will test the magnetic-based transport of NF across BBB, bio-distribution, PK-PD studies, and therapeutic efficiency of the developed NF.
